CatalystMarker
← board

CURLD

distress 0/10 · well-funded / low risk
$9.35-7%today-34% from 52w high
curaleaf.com5,554 employeesStamford, CTDrug Manufacturers - Specialty & Generic
Revenue
$1268M
Liquidity
$104M
Runway
Shares 1y
+9%

Price & events

+19.9% over 6M
$5.67$8.82$11.97Jan 26Apr 26Jul 262.5M
CatalystRating changeDilutionFinancingdashed = today
-7.1%
1D
-1.2%
1W
-2.4%
1M
+14.6%
3M
+17.2%
6M
+209.8%
1Y
2Y
5Y
+90.0%
All

Overview

Market Cap
$5.83B
Enterprise Value
$6.24B
Volume
53.20K
52 Week Range
$2.46 – $14.10
Total Shares
623.52M
Float Shares
225.89M
% Held by Insiders
25.82%
% Held by Institutions
7.38%
RVOL
0.21x
Beta
1.64

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 623,520,125 · 0 offerings/1y · 0 PIPEs
  • none
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

strong buy · target $15 (+60% upside) · 2 analysts
  • no recent rating changes

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.